Formosa Pharmaceuticals, Inc. (TPE:6838)

Taiwan · Delayed Price · Currency is TWD

24.65

-0.30 (-1.20%)

At close: Jun 18, 2026

-30.95% (1Y)

Market Cap	3.72B -5.4%
Revenue (ttm)	54.32M +236.4%
Net Income	-58.08M
EPS	-0.38
Shares Out	150.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,594
Open	25.00
Previous Close	24.95
Day's Range	24.65 - 25.10
52-Week Range	24.05 - 43.45
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and color... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6838

Full Company Profile

Financial Performance

In 2025, Formosa Pharmaceuticals's revenue was 9.50 million, a decrease of -93.38% compared to the previous year's 143.36 million. Losses were -83.57 million, -58.43% less than in 2024.

Financial Statements